- Company
- World's first Apixaban long-acting injection (LAI) by C-TRI
- by Lee, Seok-Jun Nov 11, 2019 10:41pm
- C-TRI acquired world patent for LAI containing anti-coagulant, apixaban. Apixaban is a mega drug with global sales of $9.9 billion last year. C-TRI announced on November 8 that it acquired a patent for a method for manufacturing LAI containing Apixaban using platform technology. It is a source technology for producing microspheres that
- Company
- Mavyret’s 8-week indication approved in Korea
- by Eo, Yun-Ho Nov 11, 2019 10:40pm
- A hepatitis C treatment Mavyret is to soon be available as an eight-week treatment in Korea, after its approval in the U.S. After receiving an approval from the U.S. Food and Drug Administration (FDA) first, AbbVie received an approval from Korean Ministry of Food and Drug Safety (MFDS) last month for another indication as an eight-wee
- Company
- Generic to pay for original’s lowered pricing loss?
- by Kim, Jin-Gu Nov 8, 2019 08:55am
- To this date, a boundary of patent infringement damage against generic was up to ‘sales profit of generic’. But now a lawsuit claims the damages should include ‘loss made from original’s price reduction’ due to generics’ launch. Related court case is currently waiting for the Supreme Court’s final decision. Lilly Korea and two Kor
- Company
- Carcinogen impact halves Zantac global sales
- by An, Kyung-Jin Nov 7, 2019 08:55am
- Suspected sales damage due to impurity found ranitidine came true for global pharmaceutical company Sanofi-Aventis’ Zantac. On Oct. 31, Sanofi reported global net sales of the company’s third-quarter 2019 rose by 1.1 percent over a year to EUR 9.5 billion (about 12.4 trillion won). Mainly driven by new atopic dermatitis treatmen
- Company
- Scouting fresh face for CEO at merged BMS and Celgene
- by Eo, Yun-Ho Nov 7, 2019 08:54am
- Merged Korean branch of Korea Bristol-Myers Squibb (BMS) and Celgene has now high probability of bringing in a new chief executive officer from outside of the company. According to pharmaceutical industry, BMS and Celgene headquarters have agreed on scouting a CEO openly for the merged Korean office scheduled to open before next year.
- Company
- Kisqali gets a nod from MFDS joining Ibrance and Verzenio
- by Eo, Yun-Ho Nov 6, 2019 09:00am
- Following the footsteps of Ibrance and Verzenio, a third CDK4/6 inhibitor announced its launch in Korean market. On Oct. 30, Novartis officially released news that Kisqali (ribociclib) has been approved by Ministry of Food and Drug Safety (MFDS) as a treatment of postmenopausal women with hormone-receptor positive, human epidermal growth
- Company
- Korean companies competing for GSK’s OTC Drugs
- by Jung, Hye-Jin Nov 6, 2019 09:00am
- A pharmaceutical industry insider reported on Nov. 1 that three Korean pharmaceutical companies are competing against each other to acquire sales rights of ten popular over-the-counter (OTC) drugs manufactured by GlaxoSmithKline (GSK). The multinational drug manufacturer said it would soon decide on a partner company. In 2017, GSK signed
- Company
- Is MFDS going to suspend sales on nizatidine with no NDMA?
- by Chon, Seung-Hyun Nov 6, 2019 08:59am
- Pharmaceutical industry is walking on thin ice as the government initiated impurity investigation on stomach ulcer medicine. Now that the U.S. detected impurity in nizatidine, following a case in Japan, probability of finding impurity in nizatidine has gotten higher in Korea. The industry is on high alert against the government’s possible o
- Company
- Biosimilar Ultomiris to follow Soliris next year at earliest
- by Kim, Jin-Gu Nov 4, 2019 03:12pm
- Sources predict Ultomiris would enter the Korean market and a competition against a blockbuster antibody, Soliris, next year. According to pharmaceutical industry on Oct. 30, the drug manufacturer of Ultomiris, Alexion is preparing for a launch in Korea at the end of next year. The follow-on antibody drug already has been approved by
- Company
- Companies ready litigation against valsartan damage claim
- by Chon, Seung-Hyun Nov 4, 2019 03:10pm
- The second deadline for valsartan damage indemnity payment the health authority is claiming from pharmaceutical companies has been passed. Most of companies are refusing to pay and preparing for litigation. 34 companies have decided to take a joint legal action and designated a large law firm to represent them. According to an industry insid
